Ferrokin Logo

FerroKin BioSciences is focused on the development of medicines used to manage iron for the treatment of disease. We are currently conducting worldwide clinical trials to evaluate the safety, tolerability, and iron clearing activity of FBS0701, a once daily iron-binding compound, for the treatment of transfusional iron overload.

About FerroKin BioSciences

We are working to develop a medicine that will improve the lives of patients with iron overload. Our iron-binding compound, FBS0701, is currently being evaluated in a comprehensive clinical development program.

Learn more…

About Iron Overload

Transfusional iron overload results from chronic transfusions of red blood cells. These transfusions are needed to treat certain hereditary and acquired anemias. Approximately 200 million patients worldwide suffer from anemias that require transfusions.

Learn more…

Clinical Trial

A Phase 2 study of FBS0701 in iron overloaded adults will soon begin. Learn more about active clinical trials for FBS0701 by visiting clinicaltrials.gov and entering "FerroKin" in the search box.

©2010 FerroKin BioSciences